This review emphasizes the importance of regular potassium monitoring, the potential benefits of combining therapies such as sodium-glucose cotransporter 2 (SGLT2) inhibitors with RAASi to reduce the risk of hyperkalemia, and the emergence of the newer non-steroidal MRA (nsMRA), finerenone, which may have a lower risk of hyperkalemia
Impact of semaglutide on kidney, cardiovascular, and mortality outcomes by baseline BMI and weight loss in people with T2D and CKDdata from the FLOW trial [Abstract 1971-LB]
The Wegovy prescribing information advises: patients who experience vomiting or diarrhea may need to use additional contraceptive precautions
That gap represents the difference between a good result and a transformative one for many people
These findings offer the evidence base to support the use of semaglutide 2.4 mg weekly in patients with a history of MBS and the rationale for suboptimal clinical response, posing an indication for treatment
Pairing the use of Ozempic or Wegovy with occasional alcohol use (in small amounts) may not pose any serious risk
